Lombard Odier Asset Management (Switzerland)’s 10x Genomics TXG Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-88,072	Closed	-$4.91M	–	370
2023 Q1	$4.91M	Buy	88,072 +3,596	+4%	+$168K	0.43%	64
2022 Q4	$3.08M	Buy	84,476 +20,412	+32%	+$667K	0.25%	93
2022 Q3	$1.82M	Sell	64,064 -11,530	-15%	-$439K	0.15%	120
2022 Q2	$3.42M	Sell	75,594 -4,682	-6%	-$243K	0.29%	83
2022 Q1	$6.11M	Sell	80,276 -75,676	-49%	-$6.62M	0.48%	58
2021 Q4	$23.2M	Buy	155,952 +13,180	+9%	+$2.02M	1.48%	27
2021 Q3	$20.8M	Buy	142,772 +39,858	+39%	+$6.84M	1.29%	35
2021 Q2	$20.2M	Buy	102,914 +3,853	+4%	+$697K	1.02%	44
2021 Q1	$17.9M	Buy	+99,061	New	+$17.1M	1.19%	29

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s TXG Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of 10x Genomics (TXG) in Q2 2023, closing a stake of 88,072 shares — an estimated $4.91M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in TXG in Q1 2021 and held it in 9 quarters. The position peaked at $23.2M in Q4 2021. 274 funds tracked by Wall St. Rank hold TXG as of Q2 2023.

Lombard Odier Asset Management (Switzerland) reported no remaining 10x Genomics position as of Q2 2023 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 88,072 10x Genomics shares in Q2 2023, an estimated $4.91M.
Lombard Odier Asset Management (Switzerland) first reported a position in 10x Genomics in Q1 2021 and held it in 9 quarters.
Lombard Odier Asset Management (Switzerland)'s 10x Genomics position peaked at $23.2M in Q4 2021.
274 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.